Outcomes 10 years after randomisation
| Group <40 | Group ≥40<55 | Group ≥55 | p Value | p Value | p Value | |
|---|---|---|---|---|---|---|
| n=81 | n=179 | n=248 | <40 vs ≥40<55 | <40 vs ≥55 | ≥40<55 vs ≥55 | |
| DAS over time, mean±SD | 2.0±0.7 | 2.0±0.6 | 2.1±0.6 | 0.68 | 0.57 | 0.18 |
| ESR over time, mean±SD | 17.2±12.3 | 17.8±11.6 | 22.1±16.1 | 0.73 | 0.01 | <0.01 |
| Total SHS, 0–448 scale | ||||||
| Median (IQR) | 4.1 (1.2–12.5) | 6.5 (2.0–15.5) | 7.0 (3.0–15.5) | 0.69 | 0.57 | 0.75 |
| Mean±SD | 15.0±32.4 | 13.5±20.3 | 12.9±17.1 | |||
| SHS progression | ||||||
| Median (IQR) | 2.7 (0.0–7.0) | 3.0 (0.5–11.7) | 2.5 (0.5–8.4) | 0.54 | 0.19 | 0.15 |
| Mean±SD | 12.6±31.0 | 10.4±18.5 | 7.8±15.9 | |||
| Erosion score, 0–280 scale | ||||||
| Median (IQR) | 1.0 (0.0–3.8) | 1.3 (0.3–5.0) | 1.5 (0.5–4.0) | 0.91 | 0.37 | 0.07 |
| Mean±SD | 4.9±13.0 | 5.1±9.6 | 3.6±6.5 | |||
| Erosion progression | ||||||
| Median (IQR) | 0.8 (0.0–3.0) | 1.0 (0.0–4.0) | 0.8 (0.0–2.1) | 0.93 | 0.20 | 0.02 |
| Mean±SD | 4.3±12.7 | 4.2±8.1 | 2.5±6.2 | |||
| JSN score, 0–168 scale | ||||||
| Median (IQR) | 3.0 (0.5–8.0) | 4.0 (1.0–10.0) | 5.3 (2.0–11.5) | 0.48 | 0.73 | 0.47 |
| Mean±SD | 10.1±20.4 | 8.4±12.4 | 9.4±12.0 | |||
| JSN progression | ||||||
| Median (IQR) | 1.0 (0.0–5.0) | 1.9 (0.0–7.5) | 1.8 (0.0–5.5) | 0.36 | 0.20 | 0.49 |
| Mean±SD | 8.2±19.3 | 6.2±11.6 | 5.4±11.2 | |||
DAS, disease activity score; ESR, erythrocyte sedimentation rate; SHS, Sharp/van der Heijde score; JSN, joint space narrowing.